Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient

byInstitute for Quality and Efficiency in Health CareCredit: Institute for Quality and Efficiency in Health CareIn the summer of 2019, larotrectinib was approved as the first drug in Europe to b

Updated on: December 20,2023 19

Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient

byInstitute for Quality and Efficiency in Health CareCredit: Institute for Quality and Efficiency in Health CareIn the summer of 2019, larotrectinib was approved as the first drug in Europe to b

Updated on:December 20,2023 19

New study supports extending cervical screening intervals for people who test negative for HPV

byAlice Davies| Analysis1 June 2022Normal squamous epithelial cells from the cervix under the microscopeIn January, we wrote about thechanges to the cervical screening programme in W

Updated on: December 19,2023 23

New study supports extending cervical screening intervals for people who test negative for HPV

byAlice Davies| Analysis1 June 2022Normal squamous epithelial cells from the cervix under the microscopeIn January, we wrote about thechanges to the cervical screening programme in W

Updated on:December 19,2023 23

PSMA PET scanning can improve decision making for prostate cancer treatment

bySociety of Nuclear MedicineHeat map of prostate bed PSMA PET recurrences distribution in the miTr N0 Mo cohort (n=127 patients) mapped on a template patient’s anatomy (the green contour repres

Updated on: December 17,2023 10

PSMA PET scanning can improve decision making for prostate cancer treatment

bySociety of Nuclear MedicineHeat map of prostate bed PSMA PET recurrences distribution in the miTr N0 Mo cohort (n=127 patients) mapped on a template patient’s anatomy (the green contour repres

Updated on:December 17,2023 10

Sub-lobar surgery for peripheral non-small cell lung cancer non-inferior to lobectomy

by International Association for the Study of Lung CancerCancer cell during cell division. Credit: National Institutes of HealthA large international study of patients with non-small cell lung cancer

Updated on: December 18,2023 15

Sub-lobar surgery for peripheral non-small cell lung cancer non-inferior to lobectomy

by International Association for the Study of Lung CancerCancer cell during cell division. Credit: National Institutes of HealthA large international study of patients with non-small cell lung cancer

Updated on:December 18,2023 15

Significant treatment attrition rate seen in multiple myeloma

by Elana GotkineThere is a significant treatment attrition rate in newly diagnosed multiple myeloma (NDMM), according to a study published in the November issue ofLeukemia & Lymphoma.Victor

Updated on: December 21,2023 18

Significant treatment attrition rate seen in multiple myeloma

by Elana GotkineThere is a significant treatment attrition rate in newly diagnosed multiple myeloma (NDMM), according to a study published in the November issue ofLeukemia & Lymphoma.Victor

Updated on:December 21,2023 18

Prexigebersen–Based Therapy Induces High CR/CRi Rates in Newly Diagnosed, Relapsed/Refractory AML

August 1, 2023Caroline SeymourPrexigebersen in combination with decitabine and venetoclax demonstrated potent antitumor activity when used in the treatment of patients with newly diagnosed and relapse

Updated on: October 12,2023 26

Prexigebersen–Based Therapy Induces High CR/CRi Rates in Newly Diagnosed, Relapsed/Refractory AML

August 1, 2023Caroline SeymourPrexigebersen in combination with decitabine and venetoclax demonstrated potent antitumor activity when used in the treatment of patients with newly diagnosed and relapse

Updated on:October 12,2023 26

UGN-101 reviewed in real-world upper tract urothelial cancer setting

by Elana GotkineFor patients with upper tract urothelial cancers (UTUCs), the novel therapeutic UGN-101 seems to be effective, with an acceptable safety profile, according to research published online

Updated on: December 17,2023 6

UGN-101 reviewed in real-world upper tract urothelial cancer setting

by Elana GotkineFor patients with upper tract urothelial cancers (UTUCs), the novel therapeutic UGN-101 seems to be effective, with an acceptable safety profile, according to research published online

Updated on:December 17,2023 6

Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter Transformation

June 23, 2023Ryan ScottThe combination of venetoclax, atezolizumab, and obinutuzumab elicited responses and prolonged time progression, in patients with chronic lymphocytic leukemia with Richter trans

Updated on: October 15,2023 76

Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter Transformation

June 23, 2023Ryan ScottThe combination of venetoclax, atezolizumab, and obinutuzumab elicited responses and prolonged time progression, in patients with chronic lymphocytic leukemia with Richter trans

Updated on:October 15,2023 76

Marker for therapy response in acute myeloid leukemia identified

byGerman Cancer Research CenterCell line sensitivity and additional patient data. A IC50s for VEN of 19 AML cell lines classified as primitive (Prim-AML, n = 11) or monocytic (Mono-AML, n = 8) t

Updated on: December 21,2023 10

Marker for therapy response in acute myeloid leukemia identified

byGerman Cancer Research CenterCell line sensitivity and additional patient data. A IC50s for VEN of 19 AML cell lines classified as primitive (Prim-AML, n = 11) or monocytic (Mono-AML, n = 8) t

Updated on:December 21,2023 10

Tumor Profiling Studies Illuminate Nuances Across Malignancies

November 21, 2022Megan HollaschMolecular and immune landscapes for solid tumors are constantly evolving as precision medicine techniques become more sensitive and next-generation sequencing methods ar

Updated on: October 17,2023 205

Tumor Profiling Studies Illuminate Nuances Across Malignancies

November 21, 2022Megan HollaschMolecular and immune landscapes for solid tumors are constantly evolving as precision medicine techniques become more sensitive and next-generation sequencing methods ar

Updated on:October 17,2023 205

Targeted therapy drug helps women with aggressive breast cancer live longer

by Denise Heady,University of California, Los AngelesSenior author Dr. Dennis Slamon says “there is absolutely no reason to wait” to give women treatment that combines ribociclib with hormone th

Updated on: December 22,2023 10

Targeted therapy drug helps women with aggressive breast cancer live longer

by Denise Heady,University of California, Los AngelesSenior author Dr. Dennis Slamon says “there is absolutely no reason to wait” to give women treatment that combines ribociclib with hormone th

Updated on:December 22,2023 10

WHO moves step closer to cheaper breast cancer treatment

The World Health Organization has approved a biosimilar version of Trastuzumab—the drug used to treat breast cancer—that is generally 65 percent cheaper than the originalThe World Health Organization

Updated on: December 22,2023 16

WHO moves step closer to cheaper breast cancer treatment

The World Health Organization has approved a biosimilar version of Trastuzumab—the drug used to treat breast cancer—that is generally 65 percent cheaper than the originalThe World Health Organization

Updated on:December 22,2023 16